United Kingdom · Question · Written question
UIN 38487
Cerliponase Alfa
Original
Introduced
14 March 2025
Last action
26 March 2025 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
26 March 2025
Summary
To ask the Secretary of State for Health and Social Care, if he will hold discussions with relevant stakeholders on providing access to Brineura for patients with neuronal ceroid lipofuscinosis type 2 (CLN2).
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
14 March 2025
Written question
To ask the Secretary of State for Health and Social Care, if he will hold discussions with relevant stakeholders on providing access to Brineura for patients with neuronal ceroid lipofuscinosis type 2 (CLN2).
Source: Commons
26 March 2025
Answer
The National Institute for Health and Care Excellence (NICE) is currently developing guidance for the National Health Service on whether cerliponase alfa, also known as Brineura, can be recommended for routine NHS funding, considering real-world evidence ...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2025-03-14/38487
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1784873
- uk · wq-1784873 · source updated 26 March 2025